Pharmacological interventions for pain in children and adolescents with life-limiting conditions - Wikidata - awgldk - TriplyDB

Pharmacological interventions for pain in children and adolescents with life-limiting conditions

Pharmacological interventions for pain in children and adolescents with life-limiting conditions

http://www.wikidata.org/entity/Q24187283

about

The under reporting of recruitment strategies in research with children with life-threatening illnesses: A systematic review Paediatric palliative care and intellectual disability-A unique context.'Total Pain' in Children with Severe Neurological Impairment.

P2860

Q30847046-A18A2F40-6CA8-43EC-9506-CA7325EF47F5 Q48183684-BCB2386A-C478-4385-B5DC-AFF260CD54F8 Q49732245-4594A897-8BC5-4BB6-87DC-8DA198631255

P2860

Pharmacological interventions for pain in children and adolescents with life-limiting conditions

http://www.wikidata.org/entity/Q24187283

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Pharmacological interventions ...... with life-limiting conditions

@ast

Pharmacological interventions ...... with life-limiting conditions

@en

Pharmacological interventions ...... with life-limiting conditions

@nl

type

label

Pharmacological interventions ...... with life-limiting conditions

@ast

Pharmacological interventions ...... with life-limiting conditions

@en

Pharmacological interventions ...... with life-limiting conditions

@nl

prefLabel

Pharmacological interventions ...... with life-limiting conditions

@ast

Pharmacological interventions ...... with life-limiting conditions

@en

Pharmacological interventions ...... with life-limiting conditions

@nl

P1433

Q24187283-30E37892-6343-45AE-AD69-FB3F883F4E44

P1476

Q24187283-58121666-B4A4-4690-BA11-7769C08F39B6

P2093

Q24187283-0BFA317E-7465-4E7E-8DE3-10B41838631D

Q24187283-201F926A-E3EF-41EC-BA29-793031469C25

Q24187283-5C7914E7-1091-447F-B51D-4AF7B4A282E9

Q24187283-8718F8BC-3C0C-4A02-A3FD-34B0F75BA15A

Q24187283-AAD45886-6863-473C-8FEE-45229138DAFD

Q24187283-AC2FF2B7-B1B4-4171-BA8A-BE9613B2E766

Q24187283-D0DFB9D9-5B5D-4E77-81C1-6EA129622177

Q24187283-E9383CA7-33A2-4CE0-8264-30F4070D7CB2

P2860

Q24187283-03EEDE05-074E-4FD6-85E5-21C485B3F251

Q24187283-03F91AE5-1CA9-49B0-8144-E7EFF0CDCE35

Q24187283-147103F2-A39B-4E94-9CA2-79DD1A8108B1

Q24187283-17A74654-80F2-43B3-8E2B-95C0C464736F

Q24187283-1A5CF4C1-82DC-44B9-85D7-FB474E58235B

Q24187283-204A58A5-5641-46F2-9572-147116260C8C

Q24187283-26366C24-2969-4550-8969-8BF5EF8F85B4

Q24187283-27309482-23A3-487A-B41A-A006A606CE88

Q24187283-29A1004C-7AC5-41A9-AD12-C4B29A0AF282

Q24187283-2E6B88BF-1F63-43DE-8083-EAF2B76B462A

P304

Q24187283-030F4505-8D54-41DD-8BF2-9449DCB62874

P31

Q24187283-DC3FB743-A287-48D0-A7C5-79EF2D1C2200

P356

Q24187283-1D3A5C80-0CB5-4390-A4E3-22C496082108

P433

Q24187283-5FEFC0D3-F101-4112-B324-168CD70B52A6

P50

Q24187283-1BC9D998-3317-4097-BBF2-06B4EC496829

P577

Q24187283-B3803ED8-315C-4609-915A-7A8368D61B0E

P698

Q24187283-A5B8B415-E9F6-4C68-B432-C7DDE9C3B6DB

P921

Q24187283-5858AEBA-3D37-4F6D-B6C5-3E09933CEEB8

Q24187283-7327164A-1029-45FA-831A-231A5897FE91

P932

Q24187283-ACEB657A-5E17-4A60-9F05-22CEE8E0B5C7

P356

14651858.CD010750.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Pharmacological interventions ...... with life-limiting conditions

@en

P2093

Bridget Candy

http://www.w3.org/2001/XMLSchema#string

Emma Beecham

http://www.w3.org/2001/XMLSchema#string

Henrietta Rees

http://www.w3.org/2001/XMLSchema#string

Jo Laddie

http://www.w3.org/2001/XMLSchema#string

Louise Jones

http://www.w3.org/2001/XMLSchema#string

Myra Bluebond-Langner

http://www.w3.org/2001/XMLSchema#string

Renée McCulloch

http://www.w3.org/2001/XMLSchema#string

Richard Howard

http://www.w3.org/2001/XMLSchema#string

P2860

Transdermal fentanyl for cancer pain

Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE)

Bisphosphonate therapy for osteogenesis imperfecta

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy

Systematic review of the psychometric properties, interpretability and feasibility of self-report pain intensity measures for use in clinical trials in children and adolescents

Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.

Paediatric palliative care: development and pilot study of a 'Directory' of life-limiting conditions.

Symptoms and suffering at the end of life in children with cancer.

Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study.

P304

CD010750

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/14651858.CD010750.PUB2

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P50

Victoria Vickerstaff

P577

2015-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25768935

http://www.w3.org/2001/XMLSchema#string

P921

P932

6481584

http://www.w3.org/2001/XMLSchema#string